FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1606648030> ?p ?o ?g. }

• W1606648030 endingPage "1569" @default.
• W1606648030 startingPage "1555" @default.
• W1606648030 abstract "Bicalutamide blocks androgen action and is frequently used in men with non-metastatic, castration-resistant prostate cancer (CRPC). By reducing intracellular dihydrotestosterone, dutasteride (dual 5-alpha reductase inhibitor) could increase the effectiveness of bicalutamide in this setting. The objective of the study is therefore to prospectively evaluate dutasteride plus bicalutamide in men with asymptomatic, non-metastatic CRPC with rising prostate-specific antigen (PSA).Prostate cancer patients with rising PSA whilst on first-line androgen deprivation therapy (ADT) were randomised (1:1) in a double-blind trial to receive bicalutamide 50mg plus placebo or bicalutamide 50mg plus dutasteride 3.5mg once daily for 18 months. Randomisation was stratified by centre; treatment assignments were generated using GlaxoSmithKline's RandAll System. Subjects who completed 18 months could participate in the 2-year extension. Central laboratory and study sites/monitors remained treatment-blinded. Primary end-point was time to disease progression (TDP) up to 42 months (defined as PSA progression from baseline or nadir, radiographic disease progression, death from prostate cancer or receipt of rescue medication).There was no statistically significant difference in TDP in 127 men treated with bicalutamide/dutasteride (n=62) compared with bicalutamide/placebo (n=65) (hazard ratio (HR)=0.94 [95% confidence interval (CI) 0.61, 1.46]; p=0.79). The estimated median TDP was 425 days (95% CI 302, 858) in the bicalutamide/placebo group and 623 days (95% CI 369, 730) in the bicalutamide/dutasteride group. There was no statistically significant difference between the treatment groups for any secondary efficacy end-points, including time to treatment failure or PSA response. In the multivariate analysis, age, non-White race, higher baseline testosterone and lower baseline PSA were associated with longer TDP. Adverse events were comparable between treatment groups.In men with non-metastatic CRPC, adding dutasteride to bicalutamide did not significantly prolong TDP. Prospective data are provided concerning the common practice of using bicalutamide in this setting." @default.
• W1606648030 created "2016-06-24" @default.
• W1606648030 creator A5003454382 @default.
• W1606648030 creator A5009734851 @default.
• W1606648030 creator A5035292675 @default.
• W1606648030 creator A5037311091 @default.
• W1606648030 creator A5048746057 @default.
• W1606648030 creator A5071741514 @default.
• W1606648030 creator A5073246821 @default.
• W1606648030 date "2015-08-01" @default.
• W1606648030 modified "2023-10-18" @default.
• W1606648030 title "A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer" @default.
• W1606648030 cites W1546784169 @default.
• W1606648030 cites W1682032966 @default.
• W1606648030 cites W186194822 @default.
• W1606648030 cites W1971983943 @default.
• W1606648030 cites W1972311593 @default.
• W1606648030 cites W1979832268 @default.
• W1606648030 cites W2000853346 @default.
• W1606648030 cites W2007144541 @default.
• W1606648030 cites W2029256578 @default.
• W1606648030 cites W2033562626 @default.
• W1606648030 cites W2051049441 @default.
• W1606648030 cites W2060432974 @default.
• W1606648030 cites W2060924022 @default.
• W1606648030 cites W2073062381 @default.
• W1606648030 cites W2077301757 @default.
• W1606648030 cites W2078057935 @default.
• W1606648030 cites W2084095675 @default.
• W1606648030 cites W2087779901 @default.
• W1606648030 cites W2096544053 @default.
• W1606648030 cites W2099969339 @default.
• W1606648030 cites W2101134619 @default.
• W1606648030 cites W2110941928 @default.
• W1606648030 cites W2132315278 @default.
• W1606648030 cites W2141569270 @default.
• W1606648030 cites W2150402649 @default.
• W1606648030 cites W2150609534 @default.
• W1606648030 cites W2151547940 @default.
• W1606648030 cites W2155530804 @default.
• W1606648030 cites W2159810380 @default.
• W1606648030 cites W4238380723 @default.
• W1606648030 doi "https://doi.org/10.1016/j.ejca.2015.04.028" @default.
• W1606648030 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26048455" @default.
• W1606648030 hasPublicationYear "2015" @default.
• W1606648030 type Work @default.
• W1606648030 sameAs 1606648030 @default.
• W1606648030 citedByCount "12" @default.
• W1606648030 countsByYear W16066480302016 @default.
• W1606648030 countsByYear W16066480302018 @default.
• W1606648030 countsByYear W16066480302019 @default.
• W1606648030 countsByYear W16066480302020 @default.
• W1606648030 countsByYear W16066480302021 @default.
• W1606648030 countsByYear W16066480302022 @default.
• W1606648030 crossrefType "journal-article" @default.
• W1606648030 hasAuthorship W1606648030A5003454382 @default.
• W1606648030 hasAuthorship W1606648030A5009734851 @default.
• W1606648030 hasAuthorship W1606648030A5035292675 @default.
• W1606648030 hasAuthorship W1606648030A5037311091 @default.
• W1606648030 hasAuthorship W1606648030A5048746057 @default.
• W1606648030 hasAuthorship W1606648030A5071741514 @default.
• W1606648030 hasAuthorship W1606648030A5073246821 @default.
• W1606648030 hasConcept C121608353 @default.
• W1606648030 hasConcept C126322002 @default.
• W1606648030 hasConcept C126894567 @default.
• W1606648030 hasConcept C142724271 @default.
• W1606648030 hasConcept C143998085 @default.
• W1606648030 hasConcept C168563851 @default.
• W1606648030 hasConcept C203092338 @default.
• W1606648030 hasConcept C204787440 @default.
• W1606648030 hasConcept C27081682 @default.
• W1606648030 hasConcept C2777899217 @default.
• W1606648030 hasConcept C2777911890 @default.
• W1606648030 hasConcept C2778878792 @default.
• W1606648030 hasConcept C2779322244 @default.
• W1606648030 hasConcept C2779881493 @default.
• W1606648030 hasConcept C2780192828 @default.
• W1606648030 hasConcept C2780962315 @default.
• W1606648030 hasConcept C2781406297 @default.
• W1606648030 hasConcept C61367390 @default.
• W1606648030 hasConcept C71315377 @default.
• W1606648030 hasConcept C71924100 @default.
• W1606648030 hasConceptScore W1606648030C121608353 @default.
• W1606648030 hasConceptScore W1606648030C126322002 @default.
• W1606648030 hasConceptScore W1606648030C126894567 @default.
• W1606648030 hasConceptScore W1606648030C142724271 @default.
• W1606648030 hasConceptScore W1606648030C143998085 @default.
• W1606648030 hasConceptScore W1606648030C168563851 @default.
• W1606648030 hasConceptScore W1606648030C203092338 @default.
• W1606648030 hasConceptScore W1606648030C204787440 @default.
• W1606648030 hasConceptScore W1606648030C27081682 @default.
• W1606648030 hasConceptScore W1606648030C2777899217 @default.
• W1606648030 hasConceptScore W1606648030C2777911890 @default.
• W1606648030 hasConceptScore W1606648030C2778878792 @default.
• W1606648030 hasConceptScore W1606648030C2779322244 @default.
• W1606648030 hasConceptScore W1606648030C2779881493 @default.
• W1606648030 hasConceptScore W1606648030C2780192828 @default.
• W1606648030 hasConceptScore W1606648030C2780962315 @default.

• next